Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte Q1 Earnings Call Highlights
Humacyte NASDAQ: HUMA reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its bioengineered vascular products.
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) closed at $1.06 in the latest trading session, marking a -1.85% move from the prior day.
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $0.84, denoting a +2.66% move from the preceding trading day.
